| 0.35 0.004 (1.13%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.46 | 1-year : | 0.54 |
| Resists | First : | 0.39 | Second : | 0.46 |
| Pivot price | 0.3  |
|||
| Supports | First : | 0.31 |
Second : | 0.27 |
| MAs | MA(5) : | 0.32 |
MA(20) : | 0.3 |
| MA(100) : | 0.33  |
MA(250) : | 1.21 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 62.4 |
D(3) : | 58.9 |
| RSI | RSI(14): 62.8 |
|||
| 52-week | High : | 4.78 | Low : | 0.22 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LPTX ] has closed above the upper band by 3.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 16.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.36 - 0.36 | 0.36 - 0.36 |
| Low: | 0.33 - 0.34 | 0.34 - 0.34 |
| Close: | 0.35 - 0.35 | 0.35 - 0.35 |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Thu, 25 Sep 2025
Phase 2 Colorectal Cancer Trial Results: Leap Therapeutics' Sirexatamab Study Data Coming at ESMO 2025 - Stock Titan
Thu, 25 Sep 2025
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 - PR Newswire
Thu, 14 Aug 2025
Leap Therapeutics Slashes Workforce by 75% Despite Positive Cancer Drug Trial Results - Stock Titan
Thu, 14 Aug 2025
Leap Therapeutics Reports Second Quarter 2025 Financial Results - Yahoo Finance
Mon, 23 Jun 2025
Breakthrough: Leap's Cancer Drug Doubles Survival in Key Patient Group Amid Strategic Review - Stock Titan
Mon, 23 Jun 2025
Leap Therapeutics stock jumps after announcing strategic review process - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 16.2 (%) |
| Held by Institutions | 22 (%) |
| Shares Short | 1,640 (K) |
| Shares Short P.Month | 1,530 (K) |
| EPS | -1.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -77.3 % |
| Return on Equity (ttm) | -183.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -60 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -0.23 |
| PEG Ratio | 0 |
| Price to Book value | 2.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|